Jun. 2 at 11:26 PM
$EIKN — Quick context: market makers pressuring the entire small-cap biotech tape right now. XBI weak, low liquidity, algorithmic short-side activity, sector ETF outflows compounding. Quality names get mispriced in this environment because sector tape overwhelms individual fundamentals. Patience pays.
Why EIKN remains a high-conviction long:
SETUP:
$10.52 /
$570M mkt cap /
$596M cash / ~zero EV /
$11.02 cash floor / 22 mo runway. Stock literally trading below cash. Wedbush
$5 PT vs Street consensus
$25-34.
ASCO 2026 DATA (May 30):
• EIK1001 NSCLC: 63.1% pooled ORR (SQ 72.4% vs KN-407 ~58%); PD-L1 <1% (negative) subgroup 60% ORR (vs KN-189 historical ~32%); median DOR NSQ >11 mo
• EIK1003 PARP1+PTX: 24.5% ORR; 92% of responders had prior taxane; first clinical proof PARP1-selectivity enables chemo combos
THE MERCK SETUP — read the Fierce Pharma piece:
May 30 Fierce Pharma article: “Sac-TMT’s massive Phase 3 program has a jarring gap. Does Merck plan to close it?”
Merck has 17 Ph3 trials for sac-TMT but explicitly NO registrational study in 1L PD-L1 negative/low non-squamous NSCLC — the KEYNOTE-189 population. Fierce called the gap “jarring.”
Marjorie Green (Merck head of oncology dev) to Fierce on the ASCO sidelines: “Everyone is like, ‘When are you going to replace 189?’”
Her reasoning for the gap: sac-TMT is a topo-1 ADC and combining it with platinum chemo would require dose reductions that erode efficacy. Merck deliberately didn’t “throw the kitchen sink.”
EIK1001 fits the PD-L1 negative gap exactly:
• 60% ORR in PD-L1 <1% (vs KN-189 ~32%) — the exact segment Merck can’t reach with sac-TMT
• TLR7/8 immune-activation is orthogonal to chemo, doesn’t compromise dosing — solves the exact problem Green identified
• TeLuRide-008 reg trial PD-L1 stratified, Merck supplying pembro, designed to register the gap
• Kenneth Frazier (former Merck CEO) on EIKN board
• 3 ex-Merck execs in C-suite (Perlmutter, Baynes, Klobuchar)
• Hoki (Merck Rahway) co-author on EIK1001 melanoma poster
Probability-weighted Merck acquisition: 50-60% at
$30-60/share within 24-36 mo.
MONTE CARLO (10K iter):
Median
$13.65 (+30%) / Mean
$15.55 (+48%) / P90
$32.18 (+206%) / +
$15-30/share risk-adjusted M&A optionality.
CATALYSTS: 8 milestones in 2H 2026 alone — EIK1001-006 interim, EIK1001-005 SQ mature, EIK1003 abiraterone, EIK1004 escalation complete, EIK1006 IND.
Patience through tape weakness — catalyst path reveals value.
NFAD. DYOR.
